Advance of molecular imaging probes targeted for EphB4 receptor

Abstract

Xie Qinghua, Zhu Hua, Liu Fei, Han Xuedi, Xia Chuanqin, Yang Zhi. Advance of molecular imaging probes targeted for EphB4 receptor[J]. Journal of International Oncology, 2016, 43(11): 841-844.

［1］ Mosch B, Reissenweber B, Neuber C, et al. Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis［J］. J Oncol, 2010, 2010: 135285. DOI: 10.1155/2010/135285. ［2］ Huang G, Li M. The role of EphB4 and IGFIR expression in breast cancer cells［J］. Int J Clin Exp Pathol, 2015, 8(5): 59976004. ［3］ Ferguson BD, Liu R, Rolle CE, et al. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target［J］. PLoS One, 2013, 8(7): e67668. DOI: 10.1371/journal.pone.0067668. ［4］ Hasina R, Mollberg N, Kawada I, et al. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers［J］. Cancer Res, 2013, 73(1): 184-194. DOI: 10.1158/00085472.CAN120915. ［5］ Chen T, Liu X, Yi S, et al. EphB4 is overexpressed in gliomas and promotes the growth of glioma cells［J］. Tumor Biol, 2013, 34(1): 379-385. DOI: 10.1007/s13277-012-0560-7. ［6］ Tu Y, He S, Fu J, et al. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients［J］. Clin Transl Oncol, 2012, 14(3): 214220. DOI: 10.1007/s1209401207862. ［7］ Li M, Zhao ZW, Zhang Y, et al. Overexpression of Ephb4 is associated with carcinogenesis of gastric cancer［J］. Dig Dis Sci, 2011, 56(3): 698-706. DOI: 10.1007/s10620-010-1346-7. ［8］ Li M, Zhao Z. Clinical implications of EphB4 receptor expression in pancreatic cancer［J］. Mol Biol Rep, 2013, 40(2): 1735-1741. DOI: 10.1007/s1103301222245. ［9］ Liu R, Ferguson BD, Zhou Y, et al. EphB4 as a therapeutic target in mesothelioma［J］. BMC Cancer, 2013, 13: 269. DOI: 10.1186/1471-2407-13-269. ［10］ Lisle JE, MertensWalker I, Rutkowski R, et al. Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer［J］. Biochim Biophys Acta, 2013, 1835(2): 243-257. DOI: 10.1016/j.bbcan.2013.01.003. ［11］ Xi H Q, Wu XS, Wei B, et al. Eph receptors and ephrins as targets for cancer therapy［J］. J Cell Mol Med, 2012, 16(12): 2894-2909. DOI: 10.1111/j.15824934.2012.01612.x. ［12］ Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities［J］. Annu Rev Pharmacol Toxicol, 2015, 55: 465-487. DOI: 10.1146/annurevpharmtox-011112-140226. ［13］ GuijarroMuoz I, Sánchez A, MartínezMartínez E, et al. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab［J］. Med Oncol, 2013, 30(2): 572. DOI: 10.1007/s12032-013-0572-1. ［14］ Xiong C, Huang M, Zhang R, et al. In vivo smallanimal PET/CT of EphB4 receptors using 64Culabeled peptide［J］. J Nucl Med, 2011, 52(2): 241-248. DOI: 10.2967/jnumed.110.081943. ［15］ Huang M, Xiong C, Lu W, et al. Dualmodality micropositron emission tomography/computed tomography and nearinfrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models［J］. Mol Imaging Biol, 2014, 16(1): 74-84. DOI: 10.1007/s11307-013-0674-3. ［16］ Zhang R, Xiong C, Huang M, et al. Peptideconjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts［J］. Biomaterials, 2011, 32(25): 5872-5879. DOI: 10.1016/j.biomaterials.2011.04.070. ［17］ Noberini R, Mitra S, Salvucci O, et al. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity［J］. PLoS One, 2011, 6(12): e28611. DOI: 10.1371/journal.pone.0028611. ［18］ Chen FY, Yan JJ, Yi HX, et al. TNYL peptide functional chitosangstearate conjugate micelles for tumor specific targeting［J］. Int J Nanomedicine, 2014, 9: 4597-4608. DOI: 10.2147/IJN.S69572. ［19］ Wang Z, Sun J, Qiu Y, et al. Specific photothermal therapy to the tumors with high EphB4 receptor expression［J］. Biomaterials, 2015, 68: 32-41. DOI: 10.1016/j.biomaterials.2015.07.058. ［20］ You J, Zhang R, Xiong C, et al. Effective photothermal chemotherapy using doxorubicinloaded gold nanospheres that target EphB4 receptors in tumors［J］. Cancer Res, 2012, 72(18): 4777-4786. DOI: 10.1158/00085472.CAN-12-1003. ［21］ Xiong CY, Cao QZ, Li C. PET/CT imaging of EphB4 receptors in melanoma xenograft with a 68Galabeled cyclic TNYLRAW peptide［J］. J Nucl Med, 2013, 54 (Suppl-2): 1042. ［22］ Kaur S, Venktaraman G, Jain M, et al. Recent trends in antibodybased oncologic imaging［J］. Cancer Lett, 2012, 315(2): 97-111. DOI: 10.1016/j.canlet.2011.10.017. ［23］ Krasnoperov V, Kumar SR, Ley E, et al. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth［J］. Am J Pathol, 2010, 176(4): 2029-2038. DOI: 10.2353/ajpath.2010.090755. ［24］ Liu S, Li D, Park R, et al. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Culabeled hAb47 and hAb131 antibodies［J］. J Nucl Med, 2013, 54(7): 1094-1100. DOI: 10.2967/jnumed.112.116822. ［25］ Li D, Liu S, Liu R, et al. Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring［J］. Mol Pharm, 2013, 10(1): 329-336. DOI: 10.1021/mp300461b. ［26］ Li D, Liu S, Liu R, et al. EphB4targeted imaging with antibody h131, h131F(ab′)2 and h131Fab［J］. Mol Pharm, 2013, 10(12): 4527-4533. DOI: 10.1021/mp400354y. ［27］ Mamat C, Mosch B, Neuber C, et al. Fluorine18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidinebased radiotracer targeting the receptor tyrosine kinase EphB4［J］. Chem Med Chem, 2012, 7(11): 1991-2003. DOI: 10.1002/cmdc.201200264. ［28］ Ebert K, Wiemer J, Caballero J, et al. Development of indazolylpyrimidine derivatives as highaffine EphB4 receptor ligands and potential PET radiotracers［J］. Bioorg Med Chem, 2015, 23(17): 6025-6035. DOI: 10.1016/j.bmc.2015.06.040.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

Advance of molecular imaging probes targeted for EphB4 receptor

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments